Nijmegen, Gelderland, Netherlands
Kazumi Shiosaki
2011
50
Private company
5.2
Longwood Fund, Astellas, MPM Capital
Mitochondrial dysfunction
Acute Kidney Injury, Duchenne muscular dystrophy, Mitochondrial myopathy
small molecule drugs
We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines.